Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announces the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company and developer of IRX-101, an investigational ocular antiseptic with the potential to improve the standard of care by reducing post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. Transaction details include an upfront consideration of approximately $75 million, consisting of $37.5 million in cash and $37.5 million in Tarsus common stock, and potential approval and commercial milestone payments of up to $490 million.
Read the full article: Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical //
Source: https://www.globenewswire.com/news-release/2026/07/08/3324437/0/en/tarsus-advances-eye-care-leadership-strategy-with-acquisition-of-irenix-medical-and-late-stage-asset-irx-101.html?_gl=1*1baeqwk*_up*MQ..*_ga*ODYzMjQzMTI0LjE3ODM1NDM5ODc.*_ga_B6167QB2TF*czE3ODM1NDM5ODckbzEkZzAkdDE3ODM1NDM5ODckajYwJGwwJGgxOTk3MTg2MjI5*_ga_ERWPGTJ5X8*czE3ODM1NDM5ODckbzEkZzAkdDE3ODM1NDM5ODckajYwJGwwJGgw